In the news
With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’
| BioPharma Dive
Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma | Endpoints News
"Biotech in Boston" Event Featuring Rosana Kapeller, ROME CEO | Boston Business Journal
Rosana Kapeller Among "Disruptors" Featured on WMIF Panel | World Medical Innovation Forum
Panel: Maximizing Platform Potential, with ROME CSO Dennis Zaller | Longwood Healthcare Leaders Conference
BIO Panel on Oncology Drug Discovery Features ROME CSO Dennis Zaller | BIO International Convention
Panel: Building Strong Relationships with Boards and Investors, featuring Rosana Kapeller | Convergence Forum
Podcast: Harnessing the Power of the Repeatome with Dennis Zaller | Biotech2050 podcast
ROME honored in Endpoints 11: The top private biotechs in pursuit of new drugs | Endpoints News
The Mysterious Dark Genome: Panel Featuring Rosana Kapeller, CEO of ROME | World Medical Innovation Forum
The "Dark Genome" with Dr. Rosana Kapeller-Lieberman | GV "Theory and Practice" podcast
Kapeller's ROME bags $77M to strike gold in the backwaters of the genome | Fierce Biotech
Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry | MassBio
ROME founder Rosana Kapeller recruits a CSO from the senior ranks of a major league R&D team | Endpoints News
Companies Strain to Outdo Each Other with Work-from-Home Perks (Think Ukuleles) | Wall Street Journal
From Rio to Rome: Rosanna Kapeller on The Long Run | The Timmerman Report
At ROME Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs | Xconomy
ROME Therapeutics launches to probe junk DNA for cancer drug discovery | C&EN
ROME Therapeutics debuts with $50M and Rosana Kapeller at the helm | Fierce Biotech
GV joins $50 million round in ROME Therapeutics to research ‘junk DNA’ for cancer therapies | VentureBeat
Nimbus founder Rosana Kapeller has a new company, with $50M and an eye on the ‘repeatome’ | Endpoints News